CalciMedica Stock (NASDAQ:CALC)
Previous Close
$2.76
52W Range
$2.05 - $8.38
50D Avg
$3.44
200D Avg
$4.32
Market Cap
$38.29M
Avg Vol (3M)
$59.27K
Beta
-
Div Yield
-
CALC Company Profile
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.